Literature DB >> 20482314

Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway.

Lin Gao1, Robert S Smith, Li-Mei Chen, Karl X Chai, Lee Chao, Julie Chao.   

Abstract

We recently demonstrated that tissue kallikrein (TK) promotes keratinocyte migration through activation of protease-activated receptor-1 (PAR(1)) and transactivation of the epi-dermal growth factor receptor (EGFR). In this study, we investigated the potential role of PAR(1) in mediating the effect of TK on cancer cell migration, invasion and proliferation. Our results show that TK promotes DU145 prostate cancer cell migration in a concentration-dependent manner, but has no effect on A549 lung cancer cells. Active TK markedly increases DU145 cell migration and invasion, which are blocked by aprotinin but minimally affected by icatibant; kinin treatment has little effect. TK-induced cell migration and invasion are abolished by inhibition of PAR(1) using a pharmacological inhibitor or RNA interference. The effect of TK on cell migration and invasion are also blocked by inhibitors of protein kinase C, c-Src, matrix metalloproteinase, EGFR and extracellular signal-regulated kinase (ERK). Moreover, TK stimulates ERK phosphorylation, which is inhibited by an EGFR antagonist. Additionally, TK but not kinin stimulates DU145 cell proliferation through activation of the kinin B2 receptor, but not PAR(1) and EGFR. These results indicate differential signaling pathways mediated by TK in promoting prostate cancer cell migration and invasion via PAR(1) activation, and proliferation via kinin B2 receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482314     DOI: 10.1515/BC.2010.084

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  10 in total

Review 1.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

2.  Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.

Authors:  David C Qian; Jinyoung Byun; Younghun Han; Casey S Greene; John K Field; Rayjean J Hung; Yonathan Brhane; John R Mclaughlin; Gordon Fehringer; Maria Teresa Landi; Albert Rosenberger; Heike Bickeböller; Jyoti Malhotra; Angela Risch; Joachim Heinrich; David J Hunter; Brian E Henderson; Christopher A Haiman; Fredrick R Schumacher; Rosalind A Eeles; Douglas F Easton; Daniela Seminara; Christopher I Amos
Journal:  Hum Mol Genet       Date:  2015-10-19       Impact factor: 6.150

3.  Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma.

Authors:  Mingmei Liao; Ping Tong; Jinfeng Zhao; Yangde Zhang; Zhehai Li; Jiwei Wang; Xueping Feng; Man Hu; Yifeng Pan
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

4.  Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6.

Authors:  Jingmei Zhang; Zhirong Yang; Pengfei Li; Grant Bledsoe; Lee Chao; Julie Chao
Journal:  Mol Cell Biochem       Date:  2013-05-12       Impact factor: 3.396

Review 5.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

6.  Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Authors:  Xavier Charest-Morin; Arvind Raghavan; Matthew L Charles; Tadeusz Kolodka; Johanne Bouthillier; Mélissa Jean; Mark S Robbins; François Marceau
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

Review 7.  Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer.

Authors:  Xuan Liu; Jiahui Yu; Shangjin Song; Xiaoqiang Yue; Qi Li
Journal:  Oncotarget       Date:  2017-09-18

8.  Experimental conditions influence the formation and composition of the corona around gold nanoparticles.

Authors:  Md Nazir Hossen; Chandra Kumar Elechalawar; Virginie Sjoelund; Kathleen Moore; Robert Mannel; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  Cancer Nanotechnol       Date:  2021-01-06

9.  Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells.

Authors:  Wai Han Yiu; Dickson W L Wong; Loretta Y Y Chan; Joseph C K Leung; Kwok Wah Chan; Hui Yao Lan; Kar Neng Lai; Sydney C W Tang
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 10.  Differential signaling by protease-activated receptors: implications for therapeutic targeting.

Authors:  Tejminder S Sidhu; Shauna L French; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.